TY - JOUR
T1 - Systemic Therapies for the Management of Non–Clear Cell Renal Cell Carcinoma
T2 - What Works, What Doesn't, and What the Future Holds
AU - Zoumpourlis, Panagiotis
AU - Genovese, Giannicola
AU - Tannir, Nizar M.
AU - Msaouel, Pavlos
N1 - Funding Information:
Supported in part by the Cancer Center Support Grant to MDACC (grant P30 CA016672 ) from the National Cancer Institute of the National Institutes of Health . P.M. is supported by a Young Investigator award from the Kidney Cancer Association , a Career Development award from the American Society of Clinical Oncology , a Concept award from the United States Department of Defense , and by the MD Anderson Khalifa Scholar award. The authors would like to thank Sarah Townsend (Senior Technical Writer; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX) for editorial assistance.
Funding Information:
N.T. has received honoraria for service on scientific advisory boards for Bristol-Myers Squibb, Eli Lilly and Company, Exelixis Inc, and Nektar Therapeutics; for strategic council meetings with Eisai Inc; for steering committee meetings with Pfizer Inc; and for seminar presentations for Ono Pharmaceutical Co Ltd; and has received research funding for clinical trials from Exelixis , Calithera Biosciences , and Nektar. P.M. has received honoraria for service on a scientific advisory board for Mirati Therapeutics, BMS, and Exelixis; consulting for Axiom Healthcare Strategies; nonbranded educational programs supported by Exelixis and Pfizer ; and research funding for clinical trials from Takeda , BMS , Mirati Therapeutics , Gateway for Cancer Research , and UT MD Anderson Cancer Center . The other authors have stated that they have no conflict of interest.
Funding Information:
N.T. has received honoraria for service on scientific advisory boards for Bristol-Myers Squibb, Eli Lilly and Company, Exelixis Inc, and Nektar Therapeutics; for strategic council meetings with Eisai Inc; for steering committee meetings with Pfizer Inc; and for seminar presentations for Ono Pharmaceutical Co Ltd; and has received research funding for clinical trials from Exelixis, Calithera Biosciences, and Nektar. P.M. has received honoraria for service on a scientific advisory board for Mirati Therapeutics, BMS, and Exelixis; consulting for Axiom Healthcare Strategies; nonbranded educational programs supported by Exelixis and Pfizer; and research funding for clinical trials from Takeda, BMS, Mirati Therapeutics, Gateway for Cancer Research, and UT MD Anderson Cancer Center. The other authors have stated that they have no conflict of interest.Supported in part by the Cancer Center Support Grant to MDACC (grant P30 CA016672) from the National Cancer Institute of the National Institutes of Health. P.M. is supported by a Young Investigator award from the Kidney Cancer Association, a Career Development award from the American Society of Clinical Oncology, a Concept award from the United States Department of Defense, and by the MD Anderson Khalifa Scholar award. The authors would like to thank Sarah Townsend (Senior Technical Writer; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX) for editorial assistance.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/4
Y1 - 2021/4
N2 - Non–clear cell renal cell carcinoma (nccRCC) is a broad term that refers to a diverse group of tumors, each with its own distinct biologic and therapeutic profile. The management of nccRCCs is often based on extrapolating data from clinical trials in the more common clear cell renal cell carcinoma, but our emerging prospective and retrospective clinical experience in nccRCC allows us to make more precise recommendations tailored to each histology. The systemic therapy options for metastatic nccRCC include targeted therapies such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and, for specific rare subtypes, cytotoxic chemotherapy. Each nccRCC histology may respond differently to these regimens, which makes accurate pathologic diagnosis imperative. In the present review, we discuss the available clinical and biological data that can help guide systemic therapy recommendations for specific nccRCC subtypes.
AB - Non–clear cell renal cell carcinoma (nccRCC) is a broad term that refers to a diverse group of tumors, each with its own distinct biologic and therapeutic profile. The management of nccRCCs is often based on extrapolating data from clinical trials in the more common clear cell renal cell carcinoma, but our emerging prospective and retrospective clinical experience in nccRCC allows us to make more precise recommendations tailored to each histology. The systemic therapy options for metastatic nccRCC include targeted therapies such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and, for specific rare subtypes, cytotoxic chemotherapy. Each nccRCC histology may respond differently to these regimens, which makes accurate pathologic diagnosis imperative. In the present review, we discuss the available clinical and biological data that can help guide systemic therapy recommendations for specific nccRCC subtypes.
KW - Chromophobe renal cell carcinoma
KW - Collecting duct carcinoma
KW - MiT family translocation renal cell carcinoma
KW - Papillary renal cell carcinoma
KW - Renal medullary carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85098653347&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098653347&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2020.11.005
DO - 10.1016/j.clgc.2020.11.005
M3 - Review article
C2 - 33358151
AN - SCOPUS:85098653347
SN - 1558-7673
VL - 19
SP - 103
EP - 116
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 2
ER -